Abstract

Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment option. Based on limited evidence, it was performed in several dedicated stroke centers worldwide on selected patients. Since 2015, EVT for patients with intracranial large vessel occlusion has quickly been implemented as standard treatment in many countries worldwide, supported by the revised international guidelines based on solid evidence from multiple clinical trials. We describe the development in use of EVT in the Netherlands before, during, and after the pivotal EVT trials. We used data from all patients who were treated with EVT in the Netherlands from January 2002 until December 2018. We undertook a time-series analysis to examine trends in the use of EVT using Poisson regression analysis. Incidence rate ratios per year with 95% CIs were obtained to demonstrate the impact and implementation after the publication of the EVT trial results. We made regional observation plots, adjusted for stroke incidence, to assess the availability and use of the treatment in the country. In the buildup to the MR CLEAN (Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands), a slow increase of EVT patients was observed, with 0.2% of all ischemic stroke patients receiving EVT. Before the trial results were formally announced, a statistically significant increase in EVT-treated patients per year was observed (incidence rate ratio, 1.72 [95% CI, 1.46-2.04]), and after the trial publication, an immediate steep increase was seen, followed by a more gradual increase (incidence rate ratio, 2.14 [95% CI, 1.77-2.59]). In 2018, the percentage of ischemic stroke patients receiving EVT increased to 5.8%. A well-developed infrastructure, a pragmatic approach toward the use of EVT in clinical practice, in combination with a strict adherence by the regulatory authorities to national evidence-based guidelines has led to successful implementation of EVT in the Netherlands. Ongoing efforts are directed at further increasing the proportion of stroke patients with EVT in all regions of the country.

Highlights

  • Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment option

  • We describe the trends in number of patients with acute ischemic stroke who were treated with EVT and the accessibility of EVT in the Netherlands in 3 time periods: before, during, and after the completion of the MR CLEAN trial

  • During the MR CLEAN trial (2010–2014), 500 patients were included of whom 233 patients were randomized to intervention

Read more

Summary

Introduction

Before 2015, endovascular treatment (EVT) for acute ischemic stroke was considered a promising treatment option. In the buildup to the MR CLEAN (Multicenter Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands), a slow increase of EVT patients was observed, with 0.2% of all ischemic stroke patients receiving EVT. In the Netherlands, EVT for acute ischemic stroke was not reimbursed until 2013, when reimbursement to centers was made conditional on participation in the MR CLEAN trial. In the early 2000s, 2 stroke centers started providing EVT as an experimental treatment in selected patients, inspired by the results of early trials and by local clinical experience.[10] After 2005, other centers gradually followed. 17 comprehensive stroke centers provide EVT in the Netherlands for a population of 17 182 000 inhabitants

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call